Determining Thresholds for Meaningful Change for the Headache Impact Test (HIT-6) Total and Item-Specific Scores in Chronic Migraine

被引:43
作者
Houts, Carrie R. [1 ]
Wirth, R. J. [1 ]
McGinley, James S. [1 ]
Cady, Roger [2 ]
Lipton, Richard B. [3 ]
机构
[1] Vector Psychometr Grp LLC, 847 Emily Lane, Chapel Hill, NC 27516 USA
[2] Lundbeck Seattle BioPharmaceut Inc, Neurol, Bothell, WA USA
[3] Montefiore Med Ctr, Albert Einstein Coll Med, Neurol Epidemiol & Populat Hlth, Psychiat & Behav Sci,Div Cognit Aging & Dementia, Bronx, NY 10467 USA
来源
HEADACHE | 2020年 / 60卷 / 09期
关键词
6-item short-form Headache Impact Test; minimal clinically important difference; responder definition; chronic migraine; PROMISE-2; ASSESSMENT MIDAS QUESTIONNAIRE; OUTCOMES CAMEO; EPIDEMIOLOGY; PREVALENCE; DISABILITY;
D O I
10.1111/head.13946
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective The objective of the analyses described here was to develop thresholds defining clinically meaningful response on the total and item scores of the 6-item short-form Headache Impact Test (HIT-6) in a population of patients with chronic migraine (CM). Background The HIT-6 is a short, easily understood, and useful measure of the impact of headache on daily life. Though widely used, limited literature supports a threshold value for clinically meaningful response within individuals over time for the HIT-6 total score and for the item scores, especially in the CM population. Methods PROMISE-2 is a randomized, double-blind, multicenter study comparing intravenous eptinezumab 100 and 300 mg with placebo for the preventive treatment of CM. Responder definitions for HIT-6 total and items scores using data from PROMISE-2 study were calculated via distribution-based and anchor-based methods. Distribution-based methods included half of the baseline standard deviation and baseline standard error of measurement. The change from baseline to week 12 in HIT-6 scores was assessed using the following anchors: patient global impression of change, reduction in migraine frequency, and change in EuroQol 5 dimensions 5 levels visual analog scale. Values from the literature and PROMISE-2 analyses were plotted against the cumulative distribution function of change values (baseline to week 12) and used to triangulate to empirically support clinically meaningful change definitions for the HIT-6 total and item scores in patients with CM. Results From the literature, 5 articles provided 7 candidate values for a responder threshold for the HIT-6 total score. From distribution- and anchor-based methods, 5 candidate values were derived from PROMISE-2 data. Using the median of all candidate values, a HIT-6 total score responder definition estimate of -6 (ie, >= 6-point improvement in the total score) appears most appropriate for discriminating between individuals with CM who have experienced meaningful change over time and those who have not. For item-level analyses using anchor-based methods, the responder definition for items 1-3 ("severe pain," "limits daily activities," and "lie down") was a 1-category improvement in response (eg, from Sometimes to Rarely); for items 4-6 ("too tired," "felt fed up or irritated," and "limits concentration"), a 2-category improvement in response (eg, from Always to Sometimes) was clinically meaningful. Conclusions Using a multifaceted, statistically-based approach, the recommended responder definition for the HIT-6 total score in the CM population is a >= 6-point decrease, consistent with previous literature. Anchor-based item-level responder thresholds were defined as a decrease of 1 or 2 categories, depending on the item. These CM-specific values will provide researchers and clinicians a means to interpret clinically meaningful change in the HIT-6 total and item scores and may facilitate the measurement of treatment benefits in specific functional domains of the HIT-6.
引用
收藏
页码:2003 / 2013
页数:11
相关论文
共 27 条
[1]   The impact of chronic migraine: The Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results [J].
Adams, Aubrey Manack ;
Serrano, Daniel ;
Buse, Dawn C. ;
Reed, Michael L. ;
Marske, Valerie ;
Fanning, Kristina M. ;
Lipton, Richard B. .
CEPHALALGIA, 2015, 35 (07) :563-578
[2]  
[Anonymous], 2018, PATIENT FOCUSED DRUG
[3]   Measures of Functioning in Patients With Episodic Migraine: Findings From a Double-Blind, Randomized, Placebo-Controlled Phase 2b Trial With Galcanezumab [J].
Ayer, David W. ;
Skljarevski, Vladimir ;
Ford, Janet H. ;
Nyhuis, Allen W. ;
Lipton, Richard B. ;
Aurora, Sheena K. .
HEADACHE, 2018, 58 (08) :1225-1235
[4]   Validating Migraine-Specific Quality of Life Questionnaire v2.1 in Episodic and Chronic Migraine [J].
Bagley, Christine L. ;
Rendas-Baum, Regina ;
Maglinte, Gregory A. ;
Yang, Min ;
Varon, Sepideh F. ;
Lee, Jeff ;
Kosinski, Mark .
HEADACHE, 2012, 52 (03) :409-421
[5]  
Bayliss M., 2002, The HIT-6: a user's guide
[6]   Assessment of migraine disability using the Migraine Disability Assessment (MIDAS) Questionnaire: A comparison of chronic migraine with episodic migraine [J].
Bigal, ME ;
Rapoport, AM ;
Lipton, RB ;
Tepper, SJ ;
Sheftell, FD .
HEADACHE, 2003, 43 (04) :336-342
[7]   Migraine with aura versus migraine without aura: Pain intensity and associated symptom intensities after placebo [J].
Bigal, ME ;
Bordini, CA ;
Sheftell, FD ;
Speciali, JG ;
Bigal, JOM .
HEADACHE, 2002, 42 (09) :872-877
[8]   Headache Impact of Chronic and Episodic Migraine: Results From the American Migraine Prevalence and Prevention Study [J].
Buse, Dawn ;
Manack, Aubrey ;
Serrano, Daniel ;
Reed, Michael ;
Varon, Sepideh ;
Turkel, Catherine ;
Lipton, Richard .
HEADACHE, 2012, 52 (01) :3-17
[9]   Qualitative Change in Migraine Prevention? [J].
Cady, Roger ;
Lipton, Richard B. .
HEADACHE, 2018, 58 (07) :1092-1095
[10]   Minimal clinically important change on the Headache Impact Test-6 questionnaire in patients with chronic tension-type headache [J].
Castien, Rene F. ;
Blankenstein, Annette H. ;
van der Windt, Danielle A. W. M. ;
Dekker, Joost .
CEPHALALGIA, 2012, 32 (09) :710-714